Freedom Broker raises Pfizer stock price target on strong Q3 results
Freedom Broker raised Pfizer's (PFE) price target to $34, citing strong Q3 2026 results with revenue of $16.6B and EPS of $0.87, both exceeding estimates. The company also raised its full-year guidance. Argus also raised its target to $40. PFE shares are up 26% YTD and offer a 5.76% dividend yield.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift are likely to attract buying, especially from value‑oriented investors.
Market read
Pfizer's earnings beat and raised guidance provide a fresh catalyst for short‑term price movement.
What to watch
Potential headwinds from COVID franchise decline and regulatory scrutiny on drug pricing.
Background
Pfizer reported Q3 2026 revenue of $16.6 billion and adjusted EPS of $0.87, beating estimates, and lifted its full‑year outlook.
Ticker impact
Freedom Broker raised its price target on Pfizer to $34 after the company reported strong Q3 2026 earnings and raised full-year guidance.
likely upward pressure as the market prices in the earnings beat and higher guidance
Large‑cap earnings beat with guidance lift typically drives short‑term buying interest.
Market effects
Boosts sentiment for the broader pharma sector as a leading peer shows strong earnings momentum.
U.S. market may see modest gains in healthcare indices following the release.
Limited to investors tracking large‑cap US pharma; minimal direct global impact.
Counterpoint
Some analysts may argue the guidance raise is already priced in, limiting upside.
Key entities
- companyPfizer Inc.
Large‑cap pharmaceutical company reporting Q3 2026 results.
- analystFreedom Broker
Equity research firm raising price target on Pfizer.
